Premier African Minerals Share Discussion Threads

[vitec] 09/10/2017 09:13

Just received an e-mail from TD to confirm that the shares have been deposited into my account and I have checked and they are duly sitting there.

[donald tramp] 09/10/2017 09:05

Tnx.

I think they are going in today/tomorrow vitec according to others.

[vitec] 09/10/2017 08:51

Donald, in answer to your question, the shares I purchased via Primary Bid have not been deposited into my share account as of 5 minutes ago

[donald tramp] 09/10/2017 08:49

From Gardeneye


THEN & NOW

Like many others on here I've been following the PREM story for years.
There were 4 reasons I originally invested and these still apply.
1) Circum Minerals. Even 2% was a game changer for PREM back then for the size and quality of the resource. Now 5%, it more than doubles that. It is easy to underestimate just how big, how cheap to produce and how well located Circum is for the Asian and African markets. Potash prices are once again turning around - my suspicion is that this is the time for it to be sold, when on the rise and not on it's knees. It can sell or be listed at any time. News will come out of the blue. My estimate based on the similar projects adjacent is that this will yield PREM $50m.
2) RHA. I liked RHA because it had a good historical record of production. I like Tungsten as a commodity. The whole project has been a nightmare starting with the plummeting price of APT from 450 to 150 that effectively bankrupted the entire industry. It is almost entirely due to this that the share price and the confidence in PREM and the shares in issue went out of control, diluted to death. In many ways, to have built the mine and plant in the worst possible economic climate is nothing short of miraculous and I applaud the Company for persevering. There was a very real chance PREM would have gone under had they not. APT (Tungsten) is notoriously difficult to manage. Being the second hardest mineral on the Planet it is extremely abrasive. To build this for circa $25m is also impressive. The equivalent plant and mine at Wolf Minerals cost 10x this. The breakeven point about half theirs also. When it produces 4% of the Worlds APT, this will be a fairly amazing 'against all odds' type achievement. Depending on APT ($320mtu currently and I expect it to go to $500) -Yield circa $1.25m/ month Q1 2018, plus $25m to be paid back to PREM through profits.
3) Zulu. I hunted for the cheapest possible Lithium mine I could find 3 years ago having bought into the Lithium revolution at the birth of the Tesla story which I devoured, seeing it as a fully feasible alternative to the combustion Engine. I liked their previous exploration results. That initial hunch on lithium seems to be good un. It is hardly possible to find a serious carmaker NOT committed to EV's in the next decade. The LiO energy storage industry is on the cusp of a revolution. There is simply not enough of the correct Lithium grade needed for this. The squeeze on Lithium in about 1 year is irresistible. Drill, drill and hold for this reason is precisely the right thing to do. It's an extraordinary resource and asset for PREM at this time.
4) Unlike a great deal of AIM outfits I also invested in the fact that the CEO had such a massive holding. Skin in the game is important to me. I met the team and liked their experience.
PREM really is (after a hell of a long time) FINALLY worth having a serious look at. I wish I had found debt free PREM now rather than 3 years ago.

N.B.

M/Cap is less now than 3 years ago, look how much further forward we are now, compared to then..

[vitec] 09/10/2017 08:44

Jung, I don't disagree with you just want to understand your reasoning. For the record I have been invested in PREM a lot longer than I have been invested in UKOG.

[activeservo] 09/10/2017 08:26

Many reasons.

To me they fall into the same category of AIM share. Heavily discounted, massive "potential".

Both companies in good financial position.

PREM seems to be the next UKOG in my eyes, consistent with Jung's "best AIM share" post earlier. So I assume others think the same.

The BB shows some of the UKOG posters came over here recently (including you and I....!) showing it's on the same radar as those invested in UKOG.

I noticed when UKOG topped out back in end of July those selling jumped in here...

Also, both companies are associated with DL who has a massive following.

Herd mentality.

[vitec] 09/10/2017 08:12

active, why would people be selling out of UKOG and find their way to PREM?

[activeservo] 09/10/2017 08:09

I think this should have a slight boost as people start selling out of UKOG this week.

[vitec] 09/10/2017 08:07

Mike, I agree with everything xulu has written. Every man and his dog probably understands the assets and their potential worth. What the market wants to see is this potential translated into revenue and profits. Until the evidence solidifies at the very least the share price is going to stay quagmired.

As far as throwing the kitchen sink at PREM. I have thrown the entire bathroom and kitchen suite at it and expect my reward.

[mike_f] 09/10/2017 07:44

Courtesy of Zulu on LSE:Any day now: Zulu Assays and Resource Upgrade: This will not only increase the Main Zone but add the SE Zone which is at least the same size as the Main Zone. I.e It's going to double the resource when properly drilled. It was also clearly high-grade as per the pictures. GR/DL have also implied this. Any day now: Crusher installed. 8 weeks from 31st July. XRT was limited to 55% - it will allow increase to 100%. By end of month: Additional Stope faces open at RHA underground to allow more mining of the higher grade ore. By end of month: RHA Open Pit assessment: This will be an upgraded resource model of the Open Pit detailed in November. As per RNS, operations will exceed previous guidance. Early November: Zulu PEA: This will establish an introductory economic analysis of the Zulu deposit - establish a basic mine plan and initial NPV for the project. Other AIM miners are 10-20% of their NPV with PEA only. By end of quarter: Zulu JV/Sale: Buyers were already lined up in Summer. They're waiting in the wings. We re-commence discussions after PEA. Latter part of Q4: RHA profitable business. Underground comfortably 6000 tonnes per month vs 4500 breakeven required. Open Pit to be added. Doubling profits at least! By end of quarter: Circum update. Culmination of build up to the liquidity event. We now own 5.2% - our NPV upto $109m.

[cambradjones] 09/10/2017 07:32

I wish i had a kitchen sink to chuck at it !

[markth126] 08/10/2017 22:16

Hope your right Jung as I have thrown kitchen sink at it after making a chunk on TRIN

[jungmana] 08/10/2017 21:47

Over last one week I have been convinced that there is no better company for a massive return than PREM on aim. Come early in the new year many will wish they had thrown the kitchen sink at this. Good luck all. The next 3 months will not be boring here.

[mike_f] 08/10/2017 20:49

Cool Druid, FO

[cool druid] 08/10/2017 12:51

[...]

Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS)
By Alliance | Fri, 6th October 2017 - 14:19

LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company.
The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin.
Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo.
The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%.
Merrill Lynch had a holding that was below the notable threshold prior to the purchase.
Motif Bio shares were up 6% on Friday at 46.11 pence.
By Joshua Warner; [e-mail]; @JoshAlliance

Read more:

A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure.
Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment

[donald tramp] 07/10/2017 19:29

I think that would make me a squillionaire if we hit 2p..... Or should I say when we hit 2p.

[mike_f] 07/10/2017 19:10

cambrad, I'm well underwater on a few of my purchases as well. I personally feel a JV will be forthcoming pre Christmas and think that is where we will see the greatest appreciation in price. On JV I'd be extremely upset if we didn't hit an absolute minimum of 2p.

[turbotrader2] 07/10/2017 18:28

I do not see 1p as a problem with great assays as that will lead to an even stronger PEA

[cambradjones] 07/10/2017 18:03

MikeI need a 200 % rise just to get back to my but in price about 6 weeks ago.Sickening really.

[mike_f] 07/10/2017 16:50

I agree DT, I'm just trying to be more conservative after recent events and additional shares in issue to churn along the way. Even 1p is still a 200% increase from current levels! Not bad for a few months hold...

[goodgrief] 07/10/2017 13:42

KoP, at least none of the assets are diamond mines or the Mugabes would be filling their pockets...

[merill] 07/10/2017 12:36

2 us biggies are buying Motif (MTFB). Both bought 5% each in 2 days.
Merrill Lynch


Good news hit the wires this morning from Motif Bio (LSE: MTFB), a clinical-stage biopharmaceutical company aiming to develop novel antibiotics. The market likes it and the shares are around 36% higher as I write.
The excitement surrounds details of a positive topline result from a global Phase 3 clinical trial called REVIVE-2, which is focused on the firm’s investigational drug candidate iclaprim for patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI).


A new drug is born
Chief executive Graham Lumsden tells us that today’s positive results mean the company has completed the two required Phase 3 trials in ABSSSI necessary to submit a new drug application to the US Food and Drug Administration (FDA), which Motif Bio plans to do by the end of the first quarter of 2018.
According to medical experts, ABSSSI is a serious infection and every year around 3.6m people in the US are hospitalised with it for several days. The problem with existing treatments is that they tend to be toxic to the kidneys and that’s bad because around 26% of those suffering with ABSSSI also have kidney disease. Happily, during the trial, kidney toxicity was not observed with iclaprim.
The hope now is that Iclaprim may prove to be “an important option for the growing population of patients with ABSSSI and kidney disease who need a safe and effective antibiotic targeting Gram-positive bacteria, including MRSA.” Meanwhile, from an investing point of view, the outcome of the trial means that Iclaprim now has value, which Motif Bio may be able to commercialise down the road.


Motif Bio presents drug trial data
6th October 2017 08:16 | Motif Bio Plc Ord 1p
Motif Bio has presented new pre-clinical data regarding its investigational drug candidate iclaprim to the IDWeek 2017 conference in San Diego.

"The data presented today underscore the potential utility of iclaprim in a range of patient populations with suspected MRSA infections, including cystic fibrosis patients with Staphylococcus aureus lung infections," Motif Bio chief medical officer David Huang said.


At 8:16am: (LON:MTFB) Motif Bio Plc Ord 1p share price was +0.25p at 43.75p





Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS)
By Alliance | Fri, 6th October 2017 - 14:19

LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company.
The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin.
Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo.
The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%.
Merrill Lynch had a holding that was below the notable threshold prior to the purchase.
Motif Bio shares were up 6% on Friday at 46.11 pence.
By Joshua Warner; [e-mail]; @JoshAlliance
Copyright 2017 Alliance News Limited. All Rights Reserved.


Motif Bio PLC Holding(s) in Company
05/10/2017 9:57am
UK Regulatory (RNS & others)


TIDMMTFB
RNS Number : 8030S
Motif Bio PLC
05 October 2017

NOTIFICATION OF MAJOR HOLDINGS
-----------------------------------------------------------------------------------------------------

1a. Identity of the issuer MOTIF BIO PLC
or the underlying issuer
of existing shares to which
-----------------------------------------------------------------------------------------------------
% of voting % of voting Total of Total number
rights attached rights through both in % of voting
to shares financial (8.A + 8.B) rights of
(total of instruments issuer(vii)
8. A) (total of
8.B 1 + 8.B
2)
---------------------- -------------------------- ---------------- ---------------- -------------
Resulting
situation
on the date
on which
threshold
was crossed
or reached 5.03% 5.03% 13,257,448





3. Details of person subject to the notification obligation(iv)
Name SAND GROVE CAPITAL MANAGEMENT
LLP
City and country of registered LONDON, UK
office (if applicable)
4. Full name of shareholder(s) (if different from 3.)(v)
-----------------------------------------------------------------------------------------------------
Name SAND GROVE OPPORTUNITIES
MASTER FUND LTD